(VIANEWS) – Semler Scientific (SMLR), Alkermes plc (ALKS), Badger Meter (BMI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Semler Scientific (SMLR)
21.9% sales growth and 31.8% return on equity
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, Semler Scientific has a trailing twelve months EPS of $2.5.
PE Ratio
Semler Scientific has a trailing twelve months price to earnings ratio of 18.19. Meaning, the purchaser of the share is investing $18.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.8%.
Moving Average
Semler Scientific’s value is way higher than its 50-day moving average of $37.14 and way above its 200-day moving average of $28.87.
Volume
Today’s last reported volume for Semler Scientific is 26319 which is 49.72% below its average volume of 52355.
Yearly Top and Bottom Value
Semler Scientific’s stock is valued at $45.47 at 19:22 EST, below its 52-week high of $47.93 and way above its 52-week low of $19.12.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 39% and 87.3%, respectively.
2. Alkermes plc (ALKS)
20.1% sales growth and 17.91% return on equity
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Alkermes plc has a trailing twelve months EPS of $1.24.
PE Ratio
Alkermes plc has a trailing twelve months price to earnings ratio of 22.52. Meaning, the purchaser of the share is investing $22.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.91%.
3. Badger Meter (BMI)
13.7% sales growth and 18.66% return on equity
Badger Meter, Inc. manufactures and markets flow measurement, quality, control, and communication solutions in the United States, Asia, Canada, Europe, Mexico, the Middle East, and internationally. It offers mechanical or static water meters, and related radio and software technologies and services to municipal water utilities. The company also provides flow instrumentation products, including meters, valves, and other sensing instruments to measure and control fluids going through a pipe or pipeline, including water, air, steam, oil, and other liquids and gases to original equipment manufacturers as the primary flow measurement device within a product or system, as well as through manufacturers' representatives. Its flow instrumentation products are used in water/wastewater, heating, ventilating and air conditioning, and corporate sustainability markets. In addition, the company offers ORION Migratable for automatic meter reading; ORION (SE) for traditional fixed network applications; and ORION Cellular for infrastructure-free fixed network meter reading solution, as well as BEACON advanced metering analytics, a secure cloud-hosted software suite that establishes alerts for specific conditions and allows consumer engagement tools that permit end water customers to view and manage their water usage activity. It also serves water utilities, industrial, and other industries. The company sells its products directly, as well as through resellers and representatives. Badger Meter, Inc. was founded in 1905 and is headquartered in Milwaukee, Wisconsin.
Earnings Per Share
As for profitability, Badger Meter has a trailing twelve months EPS of $2.9.
PE Ratio
Badger Meter has a trailing twelve months price to earnings ratio of 51.42. Meaning, the purchaser of the share is investing $51.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.66%.
Yearly Top and Bottom Value
Badger Meter’s stock is valued at $149.12 at 19:22 EST, way under its 52-week high of $170.86 and way higher than its 52-week low of $103.93.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.8%, now sitting on 668.48M for the twelve trailing months.
Sales Growth
Badger Meter’s sales growth is 23.8% for the present quarter and 13.7% for the next.
4. ProLogis (PLD)
13% sales growth and 6.53% return on equity
Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At September 30, 2023, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (114 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 6,700 customers principally across two major categories: business-to-business and retail/online fulfillment.
Earnings Per Share
As for profitability, ProLogis has a trailing twelve months EPS of $3.14.
PE Ratio
ProLogis has a trailing twelve months price to earnings ratio of 41.42. Meaning, the purchaser of the share is investing $41.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.53%.
Volume
Today’s last reported volume for ProLogis is 753936 which is 79.68% below its average volume of 3710880.
Moving Average
ProLogis’s value is way higher than its 50-day moving average of $117.04 and above its 200-day moving average of $119.79.
5. FTI Consulting (FCN)
10.1% sales growth and 13.72% return on equity
FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through five segments: Corporate Finance & Restructuring, Forensic and Litigation Consulting, Economic Consulting, Technology, and Strategic Communications. Its Corporate Finance & Restructuring segment provides business transformation, transactions, and turnaround and restructuring services. The company's Forensic and Litigation Consulting segment offers. construction and environmental solution, data and analytics, dispute, health solution, and risk and investigation services. Its Economic Consulting segment provides. antitrust and competition economic, financial economic, and international arbitration services. The company's Technology segment offers corporate legal operation; e-discovery and expertise; and information governance, privacy, and security services. Its Strategic Communications segment provides corporate reputation, financial communication, and public affairs services. The company serves aerospace and defense, agriculture, airlines and aviation, automotive and industrial, construction, energy, power and products, environmental solutions, financial services, healthcare and life sciences, hospitality, gaming and leisure, insurance, mining, private equity, public sector, real estate, retail and consumer products, telecom, media and technology, and transportation and logistics industries. The company was founded in 1982 and is headquartered in Washington, District of Columbia.
Earnings Per Share
As for profitability, FTI Consulting has a trailing twelve months EPS of $6.76.
PE Ratio
FTI Consulting has a trailing twelve months price to earnings ratio of 28.8. Meaning, the purchaser of the share is investing $28.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.72%.
Moving Average
FTI Consulting’s worth is below its 50-day moving average of $212.70 and higher than its 200-day moving average of $194.17.
Volume
Today’s last reported volume for FTI Consulting is 218756 which is 9.94% below its average volume of 242927.
6. EMCOR Group (EME)
9.3% sales growth and 26.59% return on equity
EMCOR Group, Inc. provides electrical and mechanical construction, and facilities services primarily in the United States and the United Kingdom. It offers design, integration, installation, starts-up, operation, and maintenance services related to electrical power transmission, distribution, and generation systems; energy solutions; premises electrical and lighting systems; process instrumentation in the refining, chemical processing, and food processing industries; low-voltage systems, such as fire alarm, security, and process control systems; voice and data communications systems; roadway and transit lighting, signaling, and fiber optic lines; heating, ventilation, air conditioning, refrigeration, and geothermal solutions; clean-room process ventilation systems; fire protection and suppression systems; plumbing, process, and high-purity piping systems; controls and filtration systems; water and wastewater treatment systems; central plant heating and cooling systems; crane and rigging services; millwright services; and steel fabrication, erection, and welding services. The company also provides building services that cover commercial and government site-based operations and maintenance; facility management, maintenance, and services; outage services to utilities and industrial plants; military base operations support services; mobile mechanical maintenance and services; services for indoor air quality; floor care and janitorial services; landscaping, lot sweeping, and snow removal services; vendor management and call center services; installation and support for building systems; program development, management, and maintenance for energy systems; technical consulting and diagnostic services; infrastructure and building projects; small modification and retrofit projects; and other building services. It offers industrial services to oil, gas, and petrochemical industries. EMCOR Group, Inc. was incorporated in 1987 and is headquartered in Norwalk, Connecticut.
Earnings Per Share
As for profitability, EMCOR Group has a trailing twelve months EPS of $11.45.
PE Ratio
EMCOR Group has a trailing twelve months price to earnings ratio of 18.55. Meaning, the purchaser of the share is investing $18.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.59%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 12.09B for the twelve trailing months.
7. Akamai Technologies (AKAM)
9.1% sales growth and 12.04% return on equity
Akamai Technologies, Inc. provides cloud services for securing, delivering, and computing content, applications, and software over the internet in the United States and internationally. The company offers cloud solutions to keep infrastructure, websites, applications, application programming interfaces, and users safe from various cyberattacks and online threats while enhancing performance. It also provides web and mobile performance solutions to enable dynamic websites and applications; media delivery solutions, including video streaming and video player services, game and software delivery, broadcast operations, authoritative domain name system, resolution, and data and analytics; and cloud computing services, such as compute, storage, networking, database, and container management services to build, deploy, and secure applications and workloads. In addition, the company offers carrier offerings, including cybersecurity protection, parental controls, DNS infrastructure and content delivery solutions; and an array of service and support to assist customers with integrating, configuring, optimizing, and managing its offerings. It sells its solutions through direct sales and service organizations, as well as through various channel partners. The company was incorporated in 1998 and is headquartered in Cambridge, Massachusetts.
Earnings Per Share
As for profitability, Akamai Technologies has a trailing twelve months EPS of $3.31.
PE Ratio
Akamai Technologies has a trailing twelve months price to earnings ratio of 34.57. Meaning, the purchaser of the share is investing $34.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.04%.
Sales Growth
Akamai Technologies’s sales growth is 7.5% for the ongoing quarter and 9.1% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 16.1% and 13.6%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.5%, now sitting on 3.74B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Akamai Technologies’s EBITDA is 56.03.
8. ICON plc (ICLR)
6.6% sales growth and 5.97% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $6.23.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 45.59. Meaning, the purchaser of the share is investing $45.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.97%.
Yearly Top and Bottom Value
ICON plc’s stock is valued at $284.05 at 19:22 EST, under its 52-week high of $288.50 and way above its 52-week low of $181.92.
